Association between serum cathepsin S and mortality in older adults

JAMA

Volumn 306, Issue 10, 2011, Pages 1113-1121

  Jobs, Elisabeth ^a,d   Ingelsson, Erik ^a,c   Risérus, Ulf ^b   Nerpin, Elisabet ^a,d   Jobs, Magnus ^d   Sundström, Johan ^b   Basu, Samar ^b,e   Larsson, Anders ^b   Lind, Lars ^b   Ärnlöv, Johan ^a,d  

^a UPPSALA UNIVERSITY   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

^c KAROLINSKA INSTITUTE   (Sweden)

^d DALARNA UNIVERSITY   (Sweden)

^e UNIVERSITÉ CLERMONT AUVERGNE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; C REACTIVE PROTEIN; CATHEPSIN S; CHOLESTEROL; CYSTATIN C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYPERTENSIVE AGENT;

AGED; AGING; ANGIOGENESIS; ARTICLE; ATHEROSCLEROTIC PLAQUE; BODY MASS; CANCER CELL; CANCER MORTALITY; CARDIOVASCULAR DISEASE; CELL MIGRATION; COHORT ANALYSIS; DIABETES MELLITUS; EDUCATION; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; FEMALE; HUMAN; HYPERTENSION; INCIDENCE; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; MORTALITY; OBESITY; PHYSICAL ACTIVITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR; SMOKING; SOCIAL STATUS; SYSTOLIC BLOOD PRESSURE; WEIGHT REDUCTION;

EID: 80052773481     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2011.1246     Document Type: Article

References (47)

1. Nakagawa TY, Brissette WH, Lira PD, et al. Impaired invariant chain degradation and antigen presentation and diminished collagen-induced arthritis in cathepsin S null mice. Immunity. 1999;10(2):207-217. (Pubitemid 29115626)
2. Liuzzo JP, Petanceska SS, Moscatelli D, Devi LA. Inflammatory mediators regulate cathepsin S in macrophages and microglia: a role in attenuating heparan sulfate interactions. Mol Med. 1999;5(5):320-333. (Pubitemid 29342967)
3. Geraghty P, Greene CM, O'Mahony M, O'Neill SJ, Taggart CC, McElvaney NG. Secretory leucocyte protease inhibitor inhibits interferon-gamma-induced cathepsin S expression. J Biol Chem. 2007;282(46):33389-33395. (Pubitemid 350159551)
4. Gupta S, Singh RK, Dastidar S, Ray A. Cysteine cathepsin S as an immunomodulatory target: present and future trends. Expert Opin Ther Targets. 2008;12(3):291-299. (Pubitemid 351419423)
5. Kitamura H, Kamon H, Sawa S, et al. IL-6-STAT3 controls intracellular MHC class II alpha beta dimer level through cathepsin S activity in dendritic cells. Immunity. 2005;23(5):491-502. (Pubitemid 41587889)
6. Ovchinnikova O, Robertson AK, Wågsäter D, et al. T-cell activation leads to reduced collagen maturation in atherosclerotic plaques of Apoe(-/-) mice. Am J Pathol. 2009;174(2):693-700.
7. Pan JH, Sukhova GK, Yang JT, et al. Macrophage migration inhibitory factor deficiency impairs atherosclerosis in low-density lipoprotein receptor-deficient mice. Circulation. 2004;109(25):3149-3153.
8. Taleb S, Lacasa D, Bastard JP, et al. Cathepsin S, a novel biomarker of adiposity: relevance to atherogenesis. FASEB J. 2005;19(11):1540-1542. (Pubitemid 41279024)
9. Williams AS, Eynott PR, Leung SY, et al. Role of cathepsin S in ozone-induced airway hyperresponsiveness and inflammation. Pulm Pharmacol Ther. 2009;22(1):27-32.
10. Bengtsson E, Nilsson J, Jovinge S. Cystatin C and cathepsins in cardiovascular disease. Front Biosci. 2008;13:5780-5786.
11. Taleb S, Cancello R, Poitou C, et al. Weight loss reduces adipose tissue cathepsin S and its circulating levels in morbidly obese women. J Clin Endocrinol Metab. 2006;91(3):1042-1047. (Pubitemid 43357778)
12. Naour N, Rouault C, Fellahi S, et al. Cathepsins in human obesity: changes in energy balance pre-dominantly affect cathepsin S in adipose tissue and in circulation. J Clin Endocrinol Metab. 2010;95(4):1861-1868.
13. Liu J, Ma L, Yang J, et al. Increased serum cathepsin S in patients with atherosclerosis and diabetes. Atherosclerosis. 2006;186(2):411-419.
14. Jobs E, Risérus U, Ingelsson E, et al. Serum cathepsin S is associated with serum C-reactive protein and interleukin-6 independently of obesity in elderly men. J Clin Endocrinol Metab. 2010;95(9):4460-4464.
15. de Nooijer R, Bot I, von der Thüsen JH, et al. Leukocyte cathepsin S is a potent regulator of both cell and matrix turnover in advanced atherosclerosis. Arterioscler Thromb Vasc Biol. 2009;29(2):188-194.
16. Jormsjö S, Wuttge DM, Sirsjö A, et al. Differential expression of cysteineandaspartic proteases during progression of atherosclerosis in apolipoprotein E-deficient mice. Am J Pathol. 2002;161(3):939-945. (Pubitemid 34988381)
17. Lindstedt L, Lee M, Oö rni K, Brömme D, Kovanen PT. Cathepsins F and S block HDL3-induced cholesterol efflux from macrophage foam cells. Biochem Biophys Res Commun. 2003;312(4):1019-1024. (Pubitemid 37490917)
18. Liu J, Sukhova GK, Sun JS, Xu WH, Libby P, Shi GP. Lysosomal cysteine proteases in atherosclerosis. Arterioscler Thromb Vasc Biol. 2004;24(8):1359-1366. (Pubitemid 39056073)
19. Rodgers KJ, Watkins DJ, Miller AL, et al. Destabilizing role of cathepsin S inmurine atherosclerotic plaques. Arterioscler Thromb Vasc Biol. 2006;26(4):851-856. (Pubitemid 43732162)
20. Sukhova GK, Zhang Y, Pan JH, et al. Deficiency of cathepsin S reduces atherosclerosis in LDL receptor-deficient mice. J Clin Invest. 2003;111(6):897-906. (Pubitemid 37074965)
21. Taleb S, Cancello R, Clément K, Lacasa D. Cathepsin S promotes human preadipocyte differentiation: possible involvement of fibronectin degradation. Endocrinology. 2006;147(10):4950-4959. (Pubitemid 44402202)
22. Burden RE, Snoddy P, Buick RJ, Johnston JA, Walker B, Scott CJ. Recombinant cathepsin Spropeptide attenuates cell invasion by inhibition of cathepsin L-like proteases intumormicroenvironment. Mol Cancer Ther.2008;7(3):538-547.
23. Fernández PL, Farré X, Nadal A, et al. Expression of cathepsins B and S in the progression of prostate carcinoma. Int J Cancer. 2001;95(1):51-55.
24. Flannery T, Gibson D, Mirakhur M, et al. The clinical significance of cathepsin S expression in human astrocytomas. Am J Pathol. 2003;163(1):175-182. (Pubitemid 36759602)
25. Kos J, Sekirnik A, Kopitar G, et al. Cathepsin S in tumours, regional lymph nodes and sera of patients with lung cancer: relation to prognosis. Br J Cancer. 2001;85(8):1193-1200. (Pubitemid 33052320)
26. Wang B, Sun J, Kitamoto S, et al. Cathepsin S controls angiogenesis and tumor growth via matrix-derived angiogenic factors. J Biol Chem. 2006;281(9):6020-6029. (Pubitemid 43847703)
27. Yang Y, Lim SK, Choong LY, et al. Cathepsin S mediates gastric cancer cell migration and invasion via a putative network of metastasis-associated proteins [published correction appears in J Proteome Res. 2010;9(12):6801]. J Proteome Res. 2010;9(9):4767-4778.
28. Byberg L, Siegbahn A, Berglund L, McKeigue P, Reneland R, Lithell H. Plasminogen activator inhibitor-1 activity is independently related to both insulin sensitivity and serum triglycerides in 70-year-old men. Arterioscler Thromb Vasc Biol. 1998;18(2):258-264. (Pubitemid 28277603)
29. Lind L, Fors N, Hall J, Marttala K, Stenborg A. A comparison of three different methods to evaluate endothelium- dependent vasodilation in the elderly: the Prospective Investigation of the Vasculature in Uppsala Seniors (PIVUS) study. Arterioscler Thromb Vasc Biol. 2005;25(11):2368-2375. (Pubitemid 41552656)
30. Zethelius B, Berglund L, Sundström J, et al. Use of multiple biomarkers to improve the prediction of death from cardiovascular causes. N Engl J Med. 2008;358(20):2107-2116. (Pubitemid 351679597)
31. Ingelsson E, Hulthe J, Lind L. Inflammatory markers in relation to insulin resistance and the metabolic syndrome. Eur J Clin Invest. 2008;38(7):502-509. (Pubitemid 351832033)
32. Urbonaviciene G, Shi GP, Urbonavicius S, Henneberg EW, Lindholt JS. Higher cystatin C level predicts long-term mortality in patients with peripheral arterial disease. Atherosclerosis. 2011;216(2):440-445.
33. Flannery T, McQuaid S, McGoohan C, et al. Cathepsin S expression: an independent prognostic factor in glioblastoma tumours - a pilot study. Int J Cancer. 2006;119(4):854-860. (Pubitemid 44051449)
34. Shlipak MG, Sarnak MJ, Katz R, et al. Cystatin C and the risk of death and cardiovascular events among elderly persons. N Engl J Med. 2005;352(20):2049-2060. (Pubitemid 40664306)
35. Wu CK, Lin JW, Caffrey JL, Chang MH, Hwang JJ, Lin YS. Cystatin C and long-term mortality among subjects with normal creatinine-based estimated glomerular filtration rates: NHANES III (Third National Health and Nutrition Examination Survey). J Am Coll Cardiol. 2010;56(23):1930-1936.
36. Sukhova GK, Shi GP, Simon DI, Chapman HA, Libby P. Expression of the elastolytic cathepsins S and K in human atheroma and regulation of their production in smooth muscle cells. J Clin Invest. 1998;102(3):576-583. (Pubitemid 28376160)
37. Schwarz G, Boehncke WH, Braun M, et al. Cathepsin S activity is detectable in human keratinocytes and is selectively upregulated upon stimulation with interferon-gamma. J Invest Dermatol. 2002;119(1):44-49. (Pubitemid 35304389)
38. Cheng XW, Zhang J, Song H, et al. Association between lysosomal cysteine protease cathepsin's activation and left ventricular function and remodeling in hypertensive heart failure rats [in Chinese]. Zhonghua Xin Xue Guan Bing Za Zhi. 2008;36(1):51-56.
39. Martin SL, Moffitt KL, McDowell A, et al. Association of airway cathepsin B and S with inflammation incystic fibrosis. Pediatr Pulmonol. 2010;45(9):860-868.
40. Chan LL, Cheung BK, Li JC, Lau AS. A role for STAT3 and cathepsin S in IL-10 down-regulation of IFN-gamma-induced MHC class II molecule on primary human blood macrophages. J Leukoc Biol. 2010;88(2):303-311.
41. Spielmann N, Mutch DM, Rousseau F, et al. Cathepsin S genotypes are associated with Apo-A1 and HDL-cholesterol in lean and obese French populations. Clin Genet. 2008;74(2):155-163. (Pubitemid 351974276)
42. Chrysant SG. Stopping the cardiovascular disease continuum: focus on prevention. World J Cardiol. 2010;2(3):43-49.
43. Aoki T, Kataoka H, Ishibashi R, Nozaki K, Hashimoto N. Cathepsin B, K, and S are expressed in cerebral aneurysms and promote the progression of cerebral aneurysms. Stroke. 2008;39(9):2603-2610.
44. Burden RE, Gormley JA, Jaquin TJ, et al. Antibody-mediated inhibition of cathepsin S blocks colorectal tumor invasion and angiogenesis. Clin Cancer Res. 2009;15(19):6042-6051.
45. Chen JC, Uang BJ, Lyu PC, et al. Design and synthesis of alpha-ketoamides as cathepsin S inhibitors with potential applications against tumor invasion and angiogenesis. J Med Chem. 2010;53(11):4545-4549.
46. Ward C, Kuehn D, Burden RE, et al. Antibody targeting of cathepsin S inhibits angiogenesis and synergistically enhances anti-VEGF. PLoS One. 2010;5(9).
47. Lee-Dutra A, Wiener DK, Sun S. Cathepsin S inhibitors: 2004-2010. Expert Opin Ther Pat. 2011;21(3):311-337.